Production (Stage)
Krystal Biotech, Inc.
KRYS
$136.94
$4.323.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 94.88% | 116.26% | 879.91% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 94.88% | 116.26% | 879.91% | -- | -- |
| Cost of Revenue | 107.85% | 72.38% | 2,897.31% | -- | -- |
| Gross Profit | 94.15% | 119.47% | 825.92% | -- | -- |
| SG&A Expenses | 25.58% | 26.34% | 21.17% | 6.65% | 8.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.88% | 27.57% | 41.56% | 29.36% | 8.56% |
| Operating Income | 522.03% | 1,218.64% | 234.39% | 155.37% | 116.01% |
| Income Before Tax | 4,577.79% | 356.13% | -63.13% | 148.31% | 102.06% |
| Income Tax Expenses | -- | 59.34% | -- | -- | -- |
| Earnings from Continuing Operations | 3,734.01% | 423.23% | -66.34% | 146.88% | 102.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3,734.01% | 423.23% | -66.34% | 146.88% | 102.06% |
| EBIT | 522.03% | 1,218.64% | 234.39% | 155.37% | 116.01% |
| EBITDA | 474.37% | 934.35% | 239.70% | 160.68% | 118.10% |
| EPS Basic | 3,669.30% | 412.51% | -67.13% | 143.70% | 101.87% |
| Normalized Basic EPS | 218.71% | 346.77% | 314.40% | 180.12% | 137.22% |
| EPS Diluted | 3,900.00% | 409.41% | -67.38% | 142.40% | 101.70% |
| Normalized Diluted EPS | 218.28% | 339.94% | 312.12% | 177.32% | 135.95% |
| Average Basic Shares Outstanding | 1.84% | 2.08% | 2.40% | 7.28% | 10.05% |
| Average Diluted Shares Outstanding | 1.98% | 3.70% | 3.50% | 11.18% | 13.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |